Llovet JM, Ricci S, Mazzaferro V, et al : Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359 (4) : 378-390, 2008.
Bruix J, Qin S, Merle P, et al : Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE) : a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 389 (10064) : 56-66, 2017.
Kudo M, Finn RS, Qin S, et al : Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet 391 (10126) : 1163-1173, 2018.
Zhu AX, Kang YK, Yen CJ, et al : Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 20 (2) : 282-296, 2019.
Finn RS, Qin S, Ikeda M, et al : Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med 382 (20) : 1894-1905, 2020.